Page 91 - GPD-2-2

Gene & Protein in Disease Verteporfin therapy for triple-negative breast cancer

A B

C D

Figure 6. VP alters G1/G0 checkpoint markers. (A and B) YAP-silenced cells exhibited increased p21 and p27 expressions while decreasing the Cyclin
D1 significantly. (C and D) VP showed the same pattern of protein expressions of p21, p27, and Cyclin D1. ***Represents P < 0.001. YAP: Yes-associated
protein; VP: Verteporfin.

A

B

D
C

E F G

Figure 7. VP stimulates apoptosis in TNBC cells. (A and B) VP treatment induced apoptosis in MDA-MB-231 cells. (C and D) siYAP-treated cells similarly
exhibited elevated apoptosis. (E–G) Immunoblots show an increased level of cleaved caspase 3 and cleaved PARP in the VP-treated groups in both TNBC
cell lines. *Represents P < 0.05, **Represents P < 0.01, and ***Represents P < 0.001. VP: Verteporfin; siYAP: Small interfering yes-associated protein;
TNBC: Triple-negative breast cancer; PARP: Poly (ADP-ribose) polymerase.

Volume 2 Issue 2 (2023) 8 https://doi.org/10.36922/gpd.0658